抗CD20嵌和抗体的体外生物学活性研究  

In vitro characterization of a chimeric anti-CD20 antibody

作　　者：杨扬[1] 张大鹏[1,2] 郭怀祖[1,2] 吴兰[1] 聂丽[2] 钱卫珠[1,2] 李博华[1,2] 

机构地区：[1]第二军医大学肿瘤研究所,上海200433 [2]上海抗体药物国家工程研究中心,上海201203

出　　处：《现代免疫学》2010年第2期95-98,共4页Current Immunology

基　　金：国家自然科学基金重点资助项目(30830109);"重大新药创制"科技重大专项(2009ZX09503-009)

摘　　要：c8F6是我们实验室制备的一株抗CD20的鼠/人嵌合抗体。本研究对c8F6的体外生物学活性进行了测定并与临床上使用的CD20抗体Rituximab进行了比较。实验结果表明,c8F6具有与Rituximab相似的抗原结合活性,抗体依赖性细胞介导的细胞毒作用(ADCC),肿瘤细胞凋亡诱导活性及肿瘤细胞生长抑制作用。但c8F6的补体依赖性细胞毒作用(CDC)明显强于Rituximab,在10μg/ml浓度时c8F6对Daudi细胞和Raji细胞的杀伤率分别为91%和86%,而Rituximab的杀伤率分别为65%(Daudi细胞)和32%(Raji细胞)。研究结果提示,c8F6可能发展成为一个比Rituximab更为有效的用于治疗B细胞非霍奇金淋巴瘤的抗体制剂。C8F6 is a chimeric anti-CD20 antibody developed in our lab. In this study, the in vitro biological activities of c8F6 was investigated and compared with that of the clinically used antibody rituximab. Our results showed that c8F6 had similar an- tigen-binding activity to rituximab. Further data indicated that c8F6 and rituximab were equally effective in mediating ADCC and inducing cell growth arrest and apoptosis in human B lymphoma cell lines Daudi and Raji. However, c8F6 exhibited much more potent CDC activity than that of rituximab. At the concentration of 10μg/ml, c8F6 could lyse 91% of Daudi cells and 86% Raji cells, while rituximab could only cause the lysis of 65% of Daudi and 32% of Raji cells. The present study suggests that c8F6 may have the potential to be developed as a more effective agent than rituximab for the treatment of B lymphoma.

关 键 词：单克隆抗体 嵌和抗体 CD20 c8F6 B细胞非霍奇金淋巴瘤 

分 类 号：R392.11[医药卫生—免疫学]